<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924946</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191137</org_study_id>
    <nct_id>NCT04924946</nct_id>
  </id_info>
  <brief_title>Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs</brief_title>
  <acronym>CUICUI-AHD</acronym>
  <official_title>Current Use in Intensive Care Units by Intensivists of Antihypertensive Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective and observational study of practices and impacts of the use of&#xD;
      antihypertensive therapies in intensive medicine and intensive care&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, prospective observational cohort study on 200 patients, by doctor's&#xD;
      questionnaire on the prescription of antihypertensive drugs in intensive care, follow-up over&#xD;
      72 hours of the prescription.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Description in number of drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Description in percentage of drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>therapeutic classes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>administration methods</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>prescription chronology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Make an inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs in intensive care and intensive care settings</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>reasons for prescribers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Time to control blood pressure values in the targeted targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Need for administration of another antihypertensive drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Disappearance of organ failure attributable to hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Weaning from an extra-renal purification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Weaning from mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for efficiency differences between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Improved kidney function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for differences in side effects between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Iatrogenic hypotension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for differences in side effects between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Need for suspension of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search for differences in side effects between the different molecules</measure>
    <time_frame>60 days after inclusion</time_frame>
    <description>Other side effect</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Antihypertensive Drugs in ICU</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inventory of prescribing habits and detect any differences in efficacy and tolerance of antihypertensive drugs</intervention_name>
    <description>Time to monitor blood pressure values in target targets&#xD;
Need for administration of another antihypertensive drug&#xD;
Disappearance of organ failure attributable to hypertension&#xD;
Weaning from an extra-renal purification&#xD;
Weaning from mechanical ventilation&#xD;
Improved kidney function&#xD;
Iatrogenic hypotension&#xD;
Need for suspension of treatment&#xD;
Other side effect</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult patients hospitalized in intensive care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Admitted to an intensive care unit&#xD;
&#xD;
          -  Patient having presented a state of circulatory shock, defined by the need for&#xD;
             continuous administration of a vasopressive amine for at least one hour, among:&#xD;
             Noradrenaline, Adrenaline&#xD;
&#xD;
          -  In whom the introduction of drug treatment for antihypertensive purposes is decided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient admitted to intensive care for a hypertensive emergency (hypertensive surge or&#xD;
             malignant arterial hypertension leading to organ dysfunction&#xD;
&#xD;
          -  Patient who has already received at least one anti-hypertensive drug during his stay&#xD;
             in intensive care&#xD;
&#xD;
          -  Cerebro-injured patient, proven or suspected cerebral edema, head trauma &lt;1 month,&#xD;
             decrease in cerebral perfusion measured&#xD;
&#xD;
          -  Proven or suspected active bleeding&#xD;
&#xD;
          -  Patient refusal of participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>GAUDRY Stephane</last_name>
    <phone>01 48 96 44 55</phone>
    <email>stephane.gaudry@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Intensive Care Victor Dupouy Hospital</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PLANTEFEVE Gaëtan</last_name>
      <phone>0134232550</phone>
      <email>gaetan.plantefeve@ch-argenteuil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Avicenne Hsopital</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAUDRY Stephane</last_name>
      <phone>01 48 96 44 55</phone>
      <email>stephane.gaudry@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Louis Mourier Hospital</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FEDERICI Laura</last_name>
      <phone>01 47 60 61 62</phone>
      <email>laura.federici@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Longjumeau Hospital</name>
      <address>
        <city>Longjumeau</city>
        <zip>91160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEMEUR Matthieu</last_name>
      <phone>01 64 54 33 33</phone>
      <email>m.lemeur@gh-nord-essonne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SONNEVLLE Romain</last_name>
      <phone>01 40 25 77 03</phone>
      <email>romain.sonneville@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care René Dubos Hospital</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THIAGARAJAH Abirami</last_name>
      <phone>01 30 75 40 40</phone>
      <email>abirami.thiagarajah@ght-novo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intensive Care Tours Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEREZ Yonathan</last_name>
      <phone>02 47 47 47 47</phone>
      <email>y.perez@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intensive care</keyword>
  <keyword>antihypertensive drugs</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

